Vanda Pharmaceuticals Inc. launches NEREUS™ (tradipitant), a newly approved NK-1 receptor antagonist for preventing motion sickness induced vomiting in adults, marking the first new treatment option in over 40 years.
Written By: Fariha Sameen, PharmD
Reviewed By: Pharmacally Editorial Team
Vanda Pharmaceuticals Inc. has announced the commercial availability of NEREUS™ (tradipitant) across the United States for the prevention of vomiting induced by motion in adults. The therapy represents the first new prescription medicine approved for this condition in more than four decades.
Motion sickness affects an estimated 65 to 78 million people in the U.S., or roughly 25% to 30% of adults, during travel by car, air, or sea. Despite its high prevalence, treatment options have remained largely unchanged for decades. NEREUS™ introduces a targeted pharmacologic approach based on neurokinin-1 (NK-1) receptor antagonism.
Tradipitant acts by blocking substance P from binding to NK-1 receptors in the central nervous system. This pathway is involved in activating the brain’s vomiting center when conflicting sensory signals arise from the eyes, inner ear, and body during motion. By inhibiting this mechanism, the drug helps prevent vomiting associated with motion sickness.
According to Mihael H. Polymeropoulos, MD, President, CEO, and Chairman of Vanda, the availability of NEREUS™ provides a new treatment option for patients experiencing motion-related symptoms. He noted that the therapy targets the biological pathway responsible for vomiting and is accessible through both retail pharmacies and a direct-to-consumer platform.
NEREUS™ is available by prescription through pharmacies nationwide and via an online ordering platform (nereus.us). Patients with a valid prescription can access the therapy at a cash-pay price of $85 per dose through the platform, compared to a standard list price of $255 per dose.
The U.S. Food and Drug Administration approved NEREUS™ on December 30, 2025, based on results from two Phase 3 trials, Motion Syros (NCT04327661) and Motion Serifos (NCT05903924). These studies were conducted under real-world sea travel conditions and showed that tradipitant significantly reduced vomiting compared with placebo.
NEREUS™ (tradipitant) is also being studied for the prevention of vomiting associated with GLP-1 receptor agonist therapies.
The treatment is administered orally, with one or two capsules taken approximately one hour before travel.
Reference